Video
Dr. Pleyer on Next Steps With Ibrutinib Plus Short-Course Fludarabine in Previously Untreated CLL
Author(s):
In Partnership With:
Christopher Pleyer, MD, discusses the next steps with the combination of ibrutinib and short-course fludarabine in previously untreated chronic lymphocytic leukemia.
Christopher Pleyer, MD, The National Heart, Lung, and Blood Institute, discusses the next steps with the combination of ibrutinib (Imbruvica) and short-course fludarabine in previously untreated chronic lymphocytic leukemia (CLL).
Data from a phase 2 pilot trial (NCT02514083) suggest that the combination of ibrutinib and short‐course fludarabine is safe and effective in patients with previously untreated CLL, says Pleyer.
Although high complete remission rates were achieved, longer follow-up data is needed to determine whether these findings can translate into long-term clinical benefit, such as improved progression-free survival and overall survival.
Looking to the future, research efforts should focus on identifying effective time-limited treatments and combination therapies that induce high rates of undetectable minimal residual disease, Pleyer concludes.
